• PCN108 - TARGETED LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN UROTHELIAL CARCINOMA

    Oct 1, 2018, 00:00

  • PDB34 - CHARACTERIZATION OF THE RISK OF DEVELOPING DIABETES MELLITUS THROUGH THE USE OF THE FINDRISC SCALE IN A VOLUNTARY INSURANCE IN COLOMBIA

    Oct 1, 2018, 00:00

  • PCN367 - HEALTH-RELATED QUALITY OF LIFE ON CÁNCER PATIENTS IN COLOMBIA

    Oct 1, 2018, 00:00

  • PIN57 - ECONOMIC ASSESSMENT OF EFFECTIVENESS AND SAFETY OF COMMON PRACTICE PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS IN A MULTIDISCIPLINARY HOSPITAL

    Oct 1, 2018, 00:00

  • PHP263 - COST EFFECTIVENESS AND COST UTILITY ANALYSIS STUDIES OF FIXED DOSE COMBINATIONS – A STUDY BASED ON PUBMED DATABASE

    Oct 1, 2018, 00:00

  • PMH56 - ACCESS TO DEMENTIA TREATMENTS IN ENGLAND; IS THIS REALLY A PRIORITY AREA FOR PRIMARY CARE?

    Oct 1, 2018, 00:00

  • PDB125 - A DISCRETE CHOICE EXERCISE TO EVALUATE FACTORS DRIVING GROWTH HORMONE DEFICIENT (GHD) PATIENT PREFERENCES FOR INJECTION AND INJECTION DEVICE FEATURES

    Oct 1, 2018, 00:00

  • PND21 - THE PREVALENCE OF MILD COGNITIVE IMPAIRMENT- A SYSTEMATIC REVIEW AND DATA SYNTHESIS

    Oct 1, 2018, 00:00

  • PHP255 - EUROPEAN “REAL-WORLD” EVIDENCE FOR DRUGS AND DEVICES- 2017 LITERATURE REVIEWED

    Oct 1, 2018, 00:00

  • PHP338 - PATIENT INVOLVEMENT IN CLINICAL PRACTICE GUIDELINE DEVELOPMENT PROCESSES- DOES REALITY ALIGN WITH INTENT?

    Oct 1, 2018, 00:00

  • PMH29 - ASSOCIATION BETWEEN HEALTHCARE COSTS AND COMORBIDITY IN PEOPLE WITH DEMENTIA

    Oct 1, 2018, 00:00

  • PHP226 - VALUE-BASED PRICING WHEN THE VALUE DIFFERS BETWEEN INDICATIONS – WHAT IS THE GERMAN WAY?

    Oct 1, 2018, 00:00

  • PCN134 - USE OF LIQUID BIOPSY IN METASTATIC NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION- A COST CONSEQUENCE ANALYSIS.

    Oct 1, 2018, 00:00

  • PRM94 - ALIGNING TEXT MINING AND MACHINE LEARNING ALGORITHMS WITH BEST PRACTICES FOR STUDY SELECTION IN SYSTEMATIC LITERATURE REVIEWS

    Oct 1, 2018, 00:00

  • PSY75 - IS DISEASE AREA A DETERMINANT OF ORPHAN DRUGS PRICES？

    Oct 1, 2018, 00:00

  • PCN294 - THE PATIENT JOURNEY OF MEN WITH LOCALISED PROSTATE CANCER- RESULTS FROM A QUALITATIVE STUDY IN GREECE

    Oct 1, 2018, 00:00

  • PCN278 - DIVERSITY OF PATIENTS PATHWAYS WITH LUNG CANCER BETWEEN 4 FRENCH REGIONS- DEFINITION OF DISSIMILARITY MEASURES

    Oct 1, 2018, 00:00

  • PMD158 - REIMBURSEMENT POLICIES AFFECT PATIENT MIGRATION

    Oct 1, 2018, 00:00

  • PHP20 - EUROPE-WIDE SPREAD OF CARBAPENEM-RESISTANT BACTERIA- EPIDEMIOLOGY AND DISEASE BURDEN

    Oct 1, 2018, 00:00

  • PND118 - PERCEPTIONS AND NEEDS OF PATIENTS WITH MIGRAINE IN GREECE- A FOCUS GROUP STUDY

    Oct 1, 2018, 00:00

  • PCN254 - TRENDS IN BRCA TESTING OVER TIME AND SOCIOECONOMIC DEPRIVATION

    Oct 1, 2018, 00:00

  • PRS105 - THE ASSESSMENT THE HEALTH UTILITIES INDEX IN CHILDREN WITH SEVERE PERSISTENT UNCONTROLLED ASTHMA, RECEIVING OMALIZUMAB

    Oct 1, 2018, 00:00

  • PHP109 - COST OF UNLICENCED AND ORPHAN MEDICINES IN TURKEY, KAZAKHSTAN AND POLAND

    Oct 1, 2018, 00:00

  • PRM85 - MACHINE LEARNING AND NATURAL LANGUAGE PROCESSING TO POWER LITERATURE SEARCH FOR TIMELY, MEANINGFUL RESULTS

    Oct 1, 2018, 00:00

  • PMD43 - BUDGET-IMPACT OF A NOVEL SURGICAL IMPLANT FOR PRIMARY OPEN-ANGLE GLAUCOMA FROM A UK HOSPITAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • Does Selecting Covariates Using Factor Analysis in Mapping Algorithms Improve Predictive Accuracy? A Case of Predicting EQ-5D-5L and SF-6D Utilities from the Women’s Health Questionnaire

    Oct 1, 2018, 00:00

  • PRM178 - CHALLENGES IN TRANSLATING 'INFLUENZA' AND ITS SYMPTOMS IN 80 LANGUAGES

    Oct 1, 2018, 00:00

  • PCN95 - A MULTICENTRIC EVALUATION OF CONSUMABLES AND TRANSPORTS COST OF BREAST CANCER PATIENT’S TREATED BY TRASTUZUMAB ACCORDING TO THE ADMINISTRATION FORM (IV VERSUS SC)

    Oct 1, 2018, 00:00

  • PMS104 - EFFICIENCY EXAMINATION OF FUNCTIONAL ELECTRICAL STIMULATION IN THE REHABILITATION OF GAIT AMONG POST-STROKE PATIENTS

    Oct 1, 2018, 00:00

  • PMS83 - COMPARISON OF FRENCH AND GERMAN HTA ASSESSMENTS FOR THREE RECENTLY EVALUATED RHEUMATOID ARTHRITIS DRUGS

    Oct 1, 2018, 00:00

  • PHP108 - DETERMINANTS OF THE UPTAKE OF ROTAVIRUS AND PNEUMOCOCCAL CONJUGATE VACCINES IN ETHIOPIA

    Oct 1, 2018, 00:00

  • PRM144 - AN OVERVIEW OF META-MODELING METHODS TO ADDRESS RUNTIME ISSUES ASSOCIATED WITH ADVANCED ANALYSES OF HEALTH ECONOMIC MODELS

    Oct 1, 2018, 00:00

  • PND6 - CHARACTERIZATION OF PREVENTIVE TREATMENT IN EPISODIC AND CHRONIC MIGRAINE PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY

    Oct 1, 2018, 00:00

  • PRS47 - PHARMACOECONOMIC ANALISYS OF PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

    Oct 1, 2018, 00:00

  • PIN72 - HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED TO THE MANAGEMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN PORTUGAL

    Oct 1, 2018, 00:00

  • PMS35 - COSTS AND HEALTH SERVICE USE ASSOCIATED WITH FLUOROQUINOLONE-RELATED TENDON INJURIES

    Oct 1, 2018, 00:00

  • PDB127 - APPLICATION OF BEST WORST SCALING TO IMPROVE PATIENT-CENTERED TREATMENT DECISIONS IN DIABETIC PERIPHERAL NEUROPATHY

    Oct 1, 2018, 00:00

  • PRM274 - SIDE-L- FRAMEWORK TO ASSESS INCLUSION OF NON-RCT DATA IN SUBMISSIONS

    Oct 1, 2018, 00:00

  • PCN264 - ASSESSMENT OF TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN SPAIN FOLLOWING INITIAL PLATINUM THERAPY FOR RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)

    Oct 1, 2018, 00:00

  • PMU109 - CONTINGENT VALUATION STUDY TO QUANTIFY THE VALUE PLACED ON THICKENERS IN THE MANAGEMENT OF DYSPHAGIA

    Oct 1, 2018, 00:00

  • PHP152 - MECHANISMS OF ILLEGAL EXPORT CAUSING DRUGS SHORTAGES IN POLAND

    Oct 1, 2018, 00:00

  • PSY68 - COSTS ASSOCIATED WITH MANAGEMENT OF ACUTE MYELOID LEUKAEMIA (AML) PATIENTS IN SPAIN

    Oct 1, 2018, 00:00

  • PMD150 - EXPENSIVE COMBINED THERAPIES FOR RARE DISEASES ARE NOT ALWAYS WHAT THEY SEEM- AN ECONOMIC FEASIBILITY AUDIT

    Oct 1, 2018, 00:00

  • PRM218 - CHARACTERISING AND APPRAISING PATIENT PREFERENCE EXPLORATION AND ELICITIATION METHODS IN THE MEDICAL PRODUCT LIFECYCLE

    Oct 1, 2018, 00:00

  • PMD172 - HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES IN FRANCE- A COLLABORATION WITH MEDICAL DEVICE MANUFACTURERS OR NATIONAL AGENCY?

    Oct 1, 2018, 00:00

  • PND22 - LEVERAGE EVIDENCE FROM OBSERVATIONAL COHORTS IN THE ELDERLY TO INFORM STUDY DESIGN OF THE INSIGHTS TO MODEL ALZHEIMER’S PROGRESSION IN REAL LIFE (IMAP) STUDY

    Oct 1, 2018, 00:00

  • PMH42 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED NORDIC COUNTRIES

    Oct 1, 2018, 00:00

  • PSY73 - ECONOMIC AND SOCIAL BURDEN OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA- A SYSTEMATIC REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PCN52 - PREVALENCE AND INCIDENCE OF DIFFERENT TYPES OF CANCER IN GERMANY- AN EPIDEMIOLOGICAL ANALYSIS BASED ON CLAIMS DATA OF MORE THAN 2.9 MILLION INSURED PERSONS

    Oct 1, 2018, 00:00

  • PCN109 - EVALUATION OF THE FACTORS AFFECTING THE COST OF PALLIATIVE CARE AT A UNIVERSITY HOSPITAL

    Oct 1, 2018, 00:00

  • PHP241 - INSIGHTS FROM PREVIOUS ATMP ASSESSMENTS IN THE UNITED KINGDOM, GERMANY AND FRANCE FOR FUTURE CAR-T REVIEWS

    Oct 1, 2018, 00:00

  • PCP37 - THE CONFIDENTIALITY REGARDING DRUGS PRICING AND REIMBURSEMENT IN ROMANIA

    Oct 1, 2018, 00:00

  • PRM20 - CLINICAL EFFECTIVENESS AND SAFETY OF STANDARD-DOSE AND LOW-DOSE NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION- A NATIONWIDE POPULATION-BASED COHORT STUDY

    Oct 1, 2018, 00:00

  • PRM100 - WEIGHTED METHOD FOR ESTIMATING INCIDENCE OF HERPES ZOSTER IN THE GENERAL POPULATION

    Oct 1, 2018, 00:00

  • PIN91 - SHORT-TERM PROJECTIONS OF EXPENDITURE ON STD/AIDS DRUGS IN A SCENARIO OF NEW REGIME OF FISCAL AUSTERITY IN BRAZIL

    Oct 1, 2018, 00:00

  • PSY30 - INCIDENCE AND PREVALENCE OF NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE IN US MEDICARE, 2008-2015

    Oct 1, 2018, 00:00

  • PRM1 - VALIDATION OF ALTERNATIVE “SURROGATE” CLINICAL ENDPOINTS IN ADVANCED MELANOMA

    Oct 1, 2018, 00:00

  • PCN115 - ASSESSING THE ECONOMIC BURDEN AND 30-DAY READMISSION RATES AMONG PATIENTS WITH BLADDER CANCER IN THE US VETERANS HEALTH ADMINISTRATION POPULATION

    Oct 1, 2018, 00:00

  • PRS91 - EVALUATING PATIENT PREFERENCES OF MAINTENANCE THERAPY FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN GERMANY- A DISCRETE CHOICE EXPERIMENT

    Oct 1, 2018, 00:00

  • PND90 - THE IMPACT OF MINISTRY OF FOOD AND DRUG SAFETY (MFDS) SAFETY NOTICE ON THE USE OF METOCLOPRAMIDE IN KOREA- A POPULATION-BASED STUDY WITH AN INTERRUPTED TIME SERIES ANALYSIS

    Oct 1, 2018, 00:00

  • PCP14 - VALUE FRAMEWORKS AND PRICING SETTING; CAN THEY CO-EXIST?

    Oct 1, 2018, 00:00

  • PCP43 - HEALTH IMPACT MODELLING (HIM)- CONCEPT, APPROACH AND REAL-WORLD DATA NEEDS FOR THE ESTIMATION OF POTENTIAL EFFECTIVENESS PROVIDED BY A PHARMA COMPANY PORTFOLIO

    Oct 1, 2018, 00:00

  • PSY34 - HEMOPHILIA B - TREATMENT PATTERNS AND EPIDEMIOLOGY INSIGHTS FROM THE GERMAN HOSPITAL QUALITY REPORTS

    Oct 1, 2018, 00:00

  • PHP184 - PATIENT INFLUENCE ON BIOSIMILAR UPTAKE- THE NOCEBO EFFECT

    Oct 1, 2018, 00:00

  • PHP168 - TRUMP’S PLANS TO REDUCE DRUG PRICES- FROM THE CAMPAIGN TRAIL TO AMERICAN PATIENTS FIRST

    Oct 1, 2018, 00:00

  • PSY155 - DETERMINING THE VALUE OF EMICIZUMAB (HEMLIBRA®) FOR THE PROPHYLAXIS TREATMENT OF HAEMOPHILIA A PATIENTS WITH INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

    Oct 1, 2018, 00:00

  • PND28 - A BUDGET IMPACT ANALYSIS OF CLADRIBINE TABLETS VERSUS ALTERNATIVE HIGH EFFICACY TREATMENTS FOR RELAPSING MULTIPLE SCLEROSIS (RMS) IN THE UNITED KINGDOM.

    Oct 1, 2018, 00:00

  • PCP49 - EXPLORING THE SENSITIVITY TO CHANGE OF THE SAMANTA QUESTIONNAIRE IN HEAVY MENSTRUAL BLEEDING- THE SAMIRA STUDY

    Oct 1, 2018, 00:00

  • PSS29 - SECUKINUMAB VERSUS ETANERCEPT FOR THE TREATMENT OF PSORIASIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN257 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) FOLLOWING INITIAL PLATINUM THERAPY IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)- A MEDICAL RECORD REVIEW IN GERMANY

    Oct 1, 2018, 00:00

  • PMS36 - SWITCH PATTERNS AND TOTAL HEALTHCARE COSTS IN BIOLOGIC-NAIVE PATIENTS INITIATING APREMILAST OR A BIOLOGIC FOR THE TREATMENT OF PSORIATIC ARTHRITIS- RESULTS FROM A US CLAIMS ANALYSIS

    Oct 1, 2018, 00:00

  • PRM250 - THE ANALYSIS OF ONCOLOGICAL PATIENT DETECTION IN MOSCOW

    Oct 1, 2018, 00:00

  • PMS32 - ASSESSING DIRECT AND INDIRECT HEALTH SYSTEM COSTS OF THE BUILD BETTER BONES WITH EXERCISE PILOT TRIAL

    Oct 1, 2018, 00:00

  • PCN22 - MARKETING AUTHORISATION PRACTICE OF THE EUROPEAN MEDICINES AGENCY (EMA) IN ONCOLOGICAL INDICATIONS

    Oct 1, 2018, 00:00

  • PRS103 - SMARTPHONE APPLICATION FOR THE ASTHMA RESEARCH IN CHILDREN AND ADOLESCENTS (ARCA) COHORT- A PILOT STUDY

    Oct 1, 2018, 00:00

  • PCV90 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR ELECTIVE TOTAL HIP REPLACEMENT SURGERY- SYSTEMATIC REVIEW, NETWORK META-ANALYSIS AND COST –UTILITY ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATION

    Oct 1, 2018, 00:00

  • PDB65 - THE COST-EFFECTIVENESS OF METFORMIN IN PRE-DIABETICS- A SYSTEMATIC LITERATURE REVIEW OF HEALTH ECONOMIC EVALUATIONS

    Oct 1, 2018, 00:00

  • DS2 - EFFECTIVENESS AND SAFETY OF STANDARD AND REDUCED DOSES OF DABIGATRAN VERSUS RIVAROXABAN IN NON-VALVULAR ATRIAL FIBRILLATION- A COHORT STUDY IN THE SNDS FRENCH NATIONWIDE CLAIMS DATABASE

    Oct 1, 2018, 00:00

  • PHP259 - PHARMACOECONOMIC GUIDELINES RECOMMENDATION FOR TURKEY CONSIDERING REFERENCE COUNTRIES

    Oct 1, 2018, 00:00

  • PMD166 - REVIEW OF NICE MEDICAL TECHNOLOGIES EVALUATION PROGRAMME (MTEP) FOR MEDICAL DEVICES

    Oct 1, 2018, 00:00

  • PSY23 - AGALSIDASE ALFA AND AGALSIDASE BETA FOR TREATMENT OF FABRY DISEASE

    Oct 1, 2018, 00:00

  • PIN81 - PHARMACISTS AS VACCINATORS- FIRST YEAR EXPERIMENTATION ON SEASONAL INFLUENZA VACCINATION IN FRANCE

    Oct 1, 2018, 00:00

  • PND156 - THE IMPACT OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (HATTR) ON WORK- THE PATIENTS’ PERSPECTIVES

    Oct 1, 2018, 00:00

  • PCV19 - PATTERNS OF ANTICOAGULATION CONTROL AND CLINICAL OUTCOMES IN ATRIAL FIBRILLATION PATIENTS TREATED WITH VITAMIN K ANTAGONISTS- A REAL-WORLD STUDY USING POPULATION-BASED DATA AND GROUP-BASED TRAJECTORY MODELS

    Oct 1, 2018, 00:00

  • PSY168 - EXPLORATORY DEVELOPMENT OF A VALUE FRAMEWORK APPROACH FOR ORPHAN MEDICINES TO INVESTIGATE THE VALUE-PRICE RELATIONSHIP

    Oct 1, 2018, 00:00

  • PHP327 - CATEGORISATION OF OBSERVATIONAL STUDIES REQUESTED BY THE EMA AND SUBMITTED TO THE EUROPEAN UNION (EU) ELECTRONIC REGISTER OF POST-AUTHORIZATION STUDIES (PAS)

    Oct 1, 2018, 00:00

  • PMD82 - COST-EFFECTIVENESS OF INSULIN PUMP THERAPY IN ADULTS WITH TYPE 1 DIABETES MELLITUS (T1DM)- THE EMIPE STUDY - A REAL-LIFE EVIDENCE STUDY IN FRANCE

    Oct 1, 2018, 00:00

  • PSY94 - COST-EFFECTIVENESS MODEL COMPARING THERAPEUTIC STRATEGIES FOR TREATING IRON DEFICIENCY ANAEMIA (IDA) IN INFLAMMATORY BOWEL DISEASE (IBD)

    Oct 1, 2018, 00:00

  • PND83 - HEALTH RESOURCE UTILIZATION ACROSS STAGES OF ALZHEIMER’S

    Oct 1, 2018, 00:00

  • Disclosure Information

    Oct 1, 2018, 00:00

  • PSY6 - EFFECTIVENESS AND SAFETY OF PEGVISOMANT- META-ANALYSIS OF OBSERVATIONAL LONGITUDINAL STUDIES

    Oct 1, 2018, 00:00

  • PGI22 - COST-EFFECTIVENESS OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UNITED KINGDOM CROHN'S DISEASE PATIENTS WHO PREVIOUSLY FAILED TNF INHIBITOR THERAPY

    Oct 1, 2018, 00:00

  • PHP61 - THE NEW AIFA INNOVATION FRAMEWORK TO RECOGNIZE INNOVATIVE DRUGS- A PRELIMINARY ANALYSIS OF KEY DRIVERS OF EVALUATION

    Oct 1, 2018, 00:00

  • PMD77 - ECONOMIC EVALUATION OF SCREENING AND PREVENTION STRATEGIES FOR OVARIAN CANCER- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PND105 - MULTIPLE SCLEROSIS- THE MAP OF PATIENT ACCESS TO DISEASE MODIFYING TREATMENTS IN EUROPE

    Oct 1, 2018, 00:00

  • PIH34 - PROGRAM 75+ - FREE MEDICINES FOR THE ELDERLY

    Oct 1, 2018, 00:00

  • PHP347 - REGULATORY, POLICY AND OPERATIONAL BARRIERS TO OUTCOME-BASED RISK SHARING AGREEMENTS IN THE U.S. MARKET- OPPORTUNITIES FOR REFORM

    Oct 1, 2018, 00:00

  • PHP28 - EXPLANATIONS FOR THE DIFFERENCES BETWEEN EFFECTS ON ADHERENCE OF VALUE-BASED HEALTH INSURANCE DESIGNS- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCN20 - CONTRIBUTION OF TRASTUZUMAB TO THE PROGNOSTIC IMPROVEMENT OF HER2-POSITIVE EARLY BREAST CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PCN126 - DIRECT COST STUDY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) FOR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM THE FRENCH HOSPITAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRS98 - SLEEP DISTURBANCE AND FATIGUE AS CONSEQUENCES OF COUGH AND MUCUS PRODUCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE- INSIGHTS FROM A PATIENT ONLINE BULLETIN BOARD STUDY

    Oct 1, 2018, 00:00

  • PHP366 - DEVELOPMENT OF THE UNIFIED SYSTEM OF ASSESSMENT OF LEVELS OF EVIDENCE AND GRADES OF RECOMMENDATIONS FOR THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PCN112 - BURDEN AND COSTS OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN PORTUGAL

    Oct 1, 2018, 00:00

  • MD2 - NETWORK META-ANALYSIS OF DIAGNOSTIC TEST ACCURACY STUDIES ALLOWING FOR MULTIPLE TESTS AT MULTIPLE THRESHOLDS FOR HEALTHCARE POLICY AND DECISION MAKING

    Oct 1, 2018, 00:00

  • PCN61 - REAL-WORLD PROGRESSION-FREE SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER- RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANY

    Oct 1, 2018, 00:00

  • PIN114 - ASSESSMENT OF THE EFFICACY AND SAFETY OF VORICONAZOLE, COMPARED WITH AVAILABLE THERAPIES IN THE TREATMENT OF PATIENTS WITH INVASIVE ASPERGILLOSIS- A NETWORD META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCP8 - BENELUXA INITIATIVE- WHY THE FIRST ATTEMPT OF JOINT ASSESSMENT FAILED?

    Oct 1, 2018, 00:00

  • PND119 - SURVEY ANALYSIS OF TREATMENT WITH INTERFERON BETA 1A IN BRAZIL AMONG MS PATIENTS PARTICIPATING IN A PATIENT SUPPORT PROGRAM (PSP)

    Oct 1, 2018, 00:00

  • PCN200 - COST-OFFSETS ASSOCIATED WITH THE NEW TRIPLETS AVAILABLE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RESOURCE CONSUMPTION DERIVED FROM ITALIAN REAL PRACTICE

    Oct 1, 2018, 00:00

  • PHP343 - CLINICAL DEVELOPMENT OF BIOLOGICS APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION, 2003-2016

    Oct 1, 2018, 00:00

  • PHP334 - PHYSICIAN-RELATED FACTORS IN DOCTOR-SHOPPING- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMS76 - HEALTHCARE RESOURCE UTILISATION ASSOCIATED WITH REFRACTORY MYASTHENIA GRAVIS (MG), IN COMPARISON TO NON-REFRACTORY MG PATIENTS IN ENGLAND- A RETROSPECTIVE COHORT STUDY.

    Oct 1, 2018, 00:00

  • PSY104 - CORE OBESITY MODEL TO ASSESS THE COST-EFFECTIVENESS OF WEIGHT MANAGEMENT INTERVENTIONS

    Oct 1, 2018, 00:00

  • PCN130 - COST ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) – A RETROSPECTIVE CLAIMS DATA ANALYSIS IN GERMANY

    Oct 1, 2018, 00:00

  • PMD49 - COST ANALYSIS OF USING THREE-DIMENSIONAL COMPLEX MAPPING CATHETER ABLATION VERSUS DRUG THERAPY FOR THE TREATMENT OF ATRIAL FIBRILLATION IN TURKEY

    Oct 1, 2018, 00:00

  • PCP52 - AN ANALYTICAL FRAMEWORK FOR EFFICACY EVALUATION OF LIGHT THERAPY IN MOOD DISORDERS- THE LINKED MECHANISMS APPROACH

    Oct 1, 2018, 00:00

  • PSY89 - COSTS AND EFFECTS OF ON-DEMAND TREATMENT OF HEREDITARY ANGIOEDEMA- A PROSPECTIVE COHORT STUDY IN ITALY

    Oct 1, 2018, 00:00

  • PMD78 - COST-EFFECTIVENESS ANALYSIS OF REAL TIME CONTINOUS GLUCOSE MONITORING (RT-CGM) VS SELF MONITORING BLOOD GLUCOSE (SMBG) IN PATIENTS WITH TYPE 1 DIABETES IN SPAIN

    Oct 1, 2018, 00:00

  • PCN69 - BUDGET IMPACT OF SUBSTITUTING BIOSIMILAR TRASTUZUMAB (CT-P6) IN TREATING GASTRIC CANCER AND BREAST CANCER IN 28 EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PMS17 - BUDGET IMPACT OF DENOSUMAB IN THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA IN COLOMBIA

    Oct 1, 2018, 00:00

  • PCV93 - COST-EFFECTIVENESS OF GUIDELINE ADHERENCE IN CORONARY PATIENTS- THE IMPACT OF THE METHODOLOGY

    Oct 1, 2018, 00:00

  • PSY12 - REAL-WORLD EFFECTIVENESS STUDY OF FERRIC CARBOXYMALTOSE IN ANAEMIC PATIENTS

    Oct 1, 2018, 00:00

  • PMS6 - EFFECTIVENESS OF BIOSSIMILARS UNDER HOSPITAL PHARMACY MANAGEMENT POLICY

    Oct 1, 2018, 00:00

  • PRM87 - CRITICAL EVALUATION OF VARIOUS DATA MINING ALGORITHMS USED FOR SIGNAL DETECTION IN FDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    Oct 1, 2018, 00:00

  • PGI21 - COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN’S DISEASE FOR TURKEY

    Oct 1, 2018, 00:00

  • PCN230 - ARE NICE AND THE SMC DIVERGING IN THEIR ASSESSMENT OF ONCOLOGY DRUGS?

    Oct 1, 2018, 00:00

  • PND98 - DETERMINING THE VALUE OF OCREVUS® (OCRELIZUMAB) FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

    Oct 1, 2018, 00:00

  • PHP22 - IS THE EUROPEAN BIOSIMILAR MEDICINES MARKET BECOMING UNSUSTAINABLE? AN EXPLORATION OF THE COMBINED IMPACT OF COMPETITION, INTERCHANGEABILITY, PROCUREMENT, AND PRICING

    Oct 1, 2018, 00:00

  • PCN297 - IMPACT OF ECONOMIC SANCTIONS ON ACCESS TO NONCOMMUNICABLE DISEASES MEDICINES IN THE ISLAMIC REPUBLIC OF IRAN

    Oct 1, 2018, 00:00

  • PIN37 - COST-EFFECTIVENESS OF ROTAVIRUS VACCINATION IN THE NETHERLANDS – A DISEASE TRANSMISSION DYNAMIC MODELING APPROACH

    Oct 1, 2018, 00:00

  • PDB113 - PSYCHOMETRIC EVALUATION OF A SELF-REPORTED MEDICATION ADHERENCE MEASURE ADAPTED TO COMMUNITY PHARMACY PRACTICE - THE QUESTIONNAIRE ” TOP SCORE "

    Oct 1, 2018, 00:00

  • PCN376 - EXAMINING CANCER RELATED DISTRESS AMONG A GROUP OF URBAN-DWELLING VETERANS.

    Oct 1, 2018, 00:00

  • PSY109 - WHAT INTERPRETATION OF ICERS IN ORPHAN DISEASES? A FRENCH EXAMPLE

    Oct 1, 2018, 00:00

  • PMD160 - PRICING OF REIMBURSED MEDICAL DEVICES IN FRANCE- WHAT FACTORS IMPACT DECISION-MAKING?

    Oct 1, 2018, 00:00

  • PUK23 - EVALUATION OF THE PROGRAM OF NEPHROPROTECTION IN PATIENTS WITH RENAL DISEASE OF A COLOMBIAN INSURANCE COMPANY

    Oct 1, 2018, 00:00

  • PRM148 - HEALTH TECHNOLOGY ASSESSMENT AGENCY APPRAISAL OF IMMUNO-ONCOLOGY CURE FRACTION SURVIVAL MODELLING

    Oct 1, 2018, 00:00

  • PMU104 - WHAT ARE THE VIEWS AND PERCEPTIONS OF THE GREEK POPULATION TOWARDS THE PHARMACEUTICAL INDUSTRY?

    Oct 1, 2018, 00:00

  • PCN285 - PRICE DIFFERENCES FOR ONCOLOGY DRUGS ACROSS THE EU-5 COUNTRIES- A COMPARATIVE ASSESSMENT.

    Oct 1, 2018, 00:00

  • ND2 - FUNCTIONAL LOSS ACROSS STAGES OF ALZHEIMER’S

    Oct 1, 2018, 00:00

  • PHP251 - PUBLIC-PRIVATE CONTRIBUTION TO BIOPHARMACEUTICAL DISCOVERIES- A BIBLIOMETRIC ANALYSIS OF BIOMEDICAL RESEARCH IN UK

    Oct 1, 2018, 00:00

  • PMH46 - A NATIONAL COMPREHENSIVE SURVEY STUDY OF PARKINSON’S DISEASE PSYCHOSIS PATIENTS AND CAREGIVERS REGARDING TIME TO PARKINSON’S DISEASE PSYCHOSIS DIAGNOSIS AND TREATMENT INITIATION

    Oct 1, 2018, 00:00

  • PRM166 - CONCEPTUALIZING A CORE DISCRETE EVENT SIMULATION MODEL TO EVALUATE THE ECONOMIC IMPACT OF ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA

    Oct 1, 2018, 00:00

  • PDB101 - THERAPY ADJUSTMENT IN ADULT T2DM PATIENTS WITH RENAL IMPAIRMENT TREATED WITH DPP-4 INHIBITORS IN THE UK- A RETROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PCP65 - KEY CONSIDERATIONS FOR THE COLLECTION OF PATIENT REPORTED OUTCOME (PRO) DATA IN REAL WORLD (RW) STUDIES

    Oct 1, 2018, 00:00

  • PCV118 - FACTORS DETERMINING SELECTION OF APPROPRIATE PATIENTS FOR PCSK9 INHIBITORS IN EUROPEAN CLINICAL PRACTICE

    Oct 1, 2018, 00:00

  • PCV10 - RANDOMISED CONTROLLED TRIALS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) – A SYSTEMATIC REVIEW (SR) OF INCLUDED PATIENT POPULATIONS

    Oct 1, 2018, 00:00

  • PCP56 - EARLY ACCESS PROGRAMS- RECOMMENDATIONS FOR REAL-WORLD DATA COLLECTION

    Oct 1, 2018, 00:00

  • DS3 - REGORAFENIB IN METASTATIC COLORECTAL CANCER- COST-EFFECTIVENESS ANALYSIS BASED ON PROPENSITY SCORE WEIGHTED COHORT OF CZECH REGISTRY

    Oct 1, 2018, 00:00

  • PRM86 - INFLAMMATORY BOWEL DISEASE AND THE COST FOR SOCIAL SECURITY SYSTEM- ESTIMATING THE PREVALENCE AND THE DISABILITY BURDEN AMONG THE ITALIAN WORKER

    Oct 1, 2018, 00:00

  • PCN327 - CHALLENGES AND OPPORTUNITIES IN CLINICAL NUTRITION IN ONCOLOGY- AVAILABLE EVIDENCE, REAL WORLD PRACTICES, AND THE WAY FORWARD

    Oct 1, 2018, 00:00

  • PIN68 - COST-EFFECTIVENESS ANALYSIS OF ISAVUCONAZOLE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PRM138 - THE DIVE FRAMEWORK FOR USING DIFFERENT TYPES OF INFORMATION IN ESTIMATING LIFETIME CLINICALLY PLAUSIBLE EFFECTIVENESS

    Oct 1, 2018, 00:00

  • PGI43 - WHAT DO PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) VALUE AND NEED? RESULTS FROM A QUANTITATIVE PATIENT PREFERENCE STUDY

    Oct 1, 2018, 00:00

  • PRM156 - THE IMPORTANCE OF ACCOUNTING FOR PARAMETER UNCERTAINTY AROUND THE SF-6D VALUE SETS AND ITS IMPACT ON STUDIES THAT USE THE SF-6D TO MEASURE HEALTH UTILITY

    Oct 1, 2018, 00:00

  • PSS17 - COST PER RESPONDER ANALYSIS OF BRODALUMAB COMPARED WITH USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA

    Oct 1, 2018, 00:00

  • PHP113 - COMPARATIVE ANALYSIS OF BIOSIMILAR RITUXIMAB USAGE IN TREATING NON-HODGKIN LYMPHOMA AND RHEUMATOID ARTHRITIS- RESULTS FROM A MULTI-COUNTRY STUDY IN EUROPE

    Oct 1, 2018, 00:00

  • PHP256 - MACHINE LEARNING TO IDENTIFY REAL-WORLD PATIENT CHARACTERISTICS ASSOCIATED WITH LENGTH OF HOSPITALIZATION

    Oct 1, 2018, 00:00

  • PDB18 - CLINICAL ECONOMIC EFFECTIVENESS OF USING VILDAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES UNDERGOING METFORMIN MONOTHERAPY WITH UNSATISFACTORY GLYCEMIC CONTROL

    Oct 1, 2018, 00:00

  • PIN128 - INSUFFICIENT DECLINE IN HIV PREVALENCE AMIDST HIGH SCORES IN HIV TESTING AND AWARENESS- A LOGISTIC MODELLING FOR HIV PREVALENCE INFORMATION AND INDIVIDUAL PROTECTIVE BEHAVIOURS IN UGANDA

    Oct 1, 2018, 00:00

  • PCN136 - A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN CANADA

    Oct 1, 2018, 00:00

  • PMU100 - MAPPING BENEFIT-RISK DECISION-MAKING PROCESSES AND IDENTIFYING DECISION POINTS WITH THE POTENTIAL TO INCLUDE PATIENT PREFERENCE INFORMATION THROUGHOUT THE MEDICAL PRODUCT LIFECYCLE

    Oct 1, 2018, 00:00

  • PMU49 - HEALTH INSURANCE COST OF PSORIASIS IN HUNGARY- COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PHP275 - ORPHAN MEDICINAL PRODUCTS GIVEN AN INITIAL NEGATIVE RECOMMENDATION BY NICE'S STA PROCESS BUT APPROVED FOLLOWING RE-EVALUATION IN ENGLAND

    Oct 1, 2018, 00:00

  • PRS90 - ASSOCIATION BETWEEN SEVERE, MODERATE AND MILD EXACERBATIONS WITH GENERIC HEALTH-RELATED QUALITY OF LIFE IN COPD PATIENTS

    Oct 1, 2018, 00:00

  • PCN179 - THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT ERYTHROPOIESIS-STIMULANTIG AGENTS FOR MANAGING CHEMOTHERAPY-INDUCED ANEMIA IN ADULT CANCER PATIENTS IN ACTUAL PRACTICE IN RUSSIA

    Oct 1, 2018, 00:00

  • PMS117 - A MULTIDSCIPLINARY STUDY ON HEALTH-RELATED QUALITY OF LIFE IN CLUBFOOT

    Oct 1, 2018, 00:00

  • PRM13 - THE FLAWED RECOMMENDATIONS OF THE SECOND PANEL ON COST-EFFECTIVENESS IN HEALTH AND MEDICINE

    Oct 1, 2018, 00:00

  • PCN150 - COST-EFFECTIVENESS ANALYSIS OF PHARMACOKINETIC-GUIDED (PK) 5-FLUOROURACIL (5-FU) DOSING WHEN COMBINED WITH LEUCOVORIN, IRINOTECAN AND OXALIPLATIN (FOLFIRINOX) CHEMOTHERAPY FOR ADVANCED PANCREAS CANCER

    Oct 1, 2018, 00:00

  • PRM89 - DATABASE ANALYSIS OF A PSP (PATIENT SUPPORT PROGRAM) FOR PATIENTS USING INTERFERON BETA-1A FOR RELAPSING MULTIPLE SCLEROSIS IN BRAZIL

    Oct 1, 2018, 00:00

  • PRM108 - EVALUATION OF CATARACT TREATMENT IN THE UNITED KINGDOM USING A PATIENT PATHWAY DISCREET EVENT SIMULATION MODEL

    Oct 1, 2018, 00:00

  • PMU65 - COST-MINIMIZATION ANALYSIS OF SMOFKABIVEN® CENTRAL FOR ADULT PATIENTS WITH IMPOSSIBLE, INSUFFICIENT OR CONTRAINDICATED ORAL OR ENTERAL NUTRITION VERSUS STANDARD ENDOVASCULAR TREATMENT IN THE MEXICAN PUBLIC HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PCN60 - REAL-WORLD OVERALL SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER- RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANY

    Oct 1, 2018, 00:00

  • PSY219 - HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PRM211 - MITIGATING EMOTIONAL BURDEN OF CONDUCTING INTERVIEWS WITH PEDIATRIC PATIENTS AND/OR THEIR CAREGIVERS ON THE INTERVIEWER- FIRST-PERSON INTERVIEWER EXPERIENCES

    Oct 1, 2018, 00:00

  • PMS68 - HOSPITAL PHARMACY CENTRALIZED PROCESS FOR HOSPITAL-WIDE MANAGEMENT OF BIOSSIMILARS USE AND ITS EFFICIENCY

    Oct 1, 2018, 00:00

  • PUK19 - COST-UTILITY OF SUCROFERRIC OXYHYDROXIDE FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING DIALYSIS IN CANADA

    Oct 1, 2018, 00:00

  • PMH35 - ECONOMIC BURDEN OF SCHIZOPHRENIA IN EUROPE

    Oct 1, 2018, 00:00

  • PMD79 - COST-EFFECTIVENESS OF ULTRASOUND-GUIDED CENTRAL VENOUS CATHETERISATION FROM THE GERMAN PAYER PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PUK21 - COST UTILITY ANALYSIS OF END STAGE RENAL DISEASE TREATMENT IN MINISTRY OF HEALTH DIALYSIS CENTRES, MALAYSIA- HAEMODIALYSIS VERSUS CONTINUOUS AMBULATORY PERITONEAL DIALYSIS

    Oct 1, 2018, 00:00

  • PUK18 - ECONOMIC EVALUATION OF THE USE OF SEVELAMER (RIFOSAR®) FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC RENAL DISEASE, FROM THE PERSPECTIVE OF THE INSTITUTO MEXICANO DEL SEGURO SOCIAL (IMSS)

    Oct 1, 2018, 00:00

  • PSS69 - APPRAISAL OF PATIENT REPORTED OUTCOME INSTRUMENTS IN INFLAMMATORY ACNE

    Oct 1, 2018, 00:00

  • PHP215 - DANISH MEDICINE COUNCIL PROCESS OF ASSESSING NEW HOSPITAL MEDICINES– FIRST YEAR OF IMPLEMENTATION

    Oct 1, 2018, 00:00

  • PRM202 - COMPARING THE EQ-5D-5L CROSSWALKS AND VALUE SETS FOR ENGLAND, THE NETHERLANDS AND SPAIN- DO CONCLUSIONS CHANGE?

    Oct 1, 2018, 00:00

  • PUK24 - HYPERKALAEMIA IN CHRONIC KIDNEY DISEASE- PATIENT TREATMENT EXPERIENCE WITH RENIN-ANGIOTENSIN-ALDOSTERONE- SYSTEM INHIBITORS IN PRIMARY CARE IN ENGLAND

    Oct 1, 2018, 00:00

  • PHP3 - SURVEY OF THE PATIENT ORGANISATION SUBMISSION PROCESS (POSP) TO THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE) IN IRELAND

    Oct 1, 2018, 00:00

  • PRM19 - REPORTING FOLLOW-UP IN SURVIVAL ANALYSES- INFORMATIVE OR NOT?

    Oct 1, 2018, 00:00

  • PMD21 - PRESSURE INJURIES IN PATIENTS WITH URINARY INCONTINENCE- EFFICACY OF REGENERA, A NEW MEDICAL DEVICE TESTED AT THE OSPEDALE MAGGIORE IN NOVARA

    Oct 1, 2018, 00:00

  • PRM247 - META-ANALYSES USING REAL-WORLD DATA- A SYSTEMATIC LITERATURE REVIEW OF EXISTING RECOMMENDATIONS

    Oct 1, 2018, 00:00

  • PIN27 - COMMUNITY-ACQUIRED PNEUMONIA HOSPITALIZATION COSTS IN THE ADULT POPULATION OF COSTA RICA FROM A PUBLIC HEALTH PERSPECTIVE OVER A 10 YEAR PERIOD (2005-2014)

    Oct 1, 2018, 00:00

  • CE3 - COST-EFFECTIVENESS OF DEMENTIA CARE MANAGEMENT ALONGSIDE A CLUSTER-RANDOMIZED CONTROLLED INTERVENTIONAL DELPHI TRIAL

    Oct 1, 2018, 00:00

  • PCN308 - DO HEALTH TECHNOLOGY APPRAISALS HAVE AN IMPACT?- A COMPARISON OF CENTRALIZED AND REGIONAL APPROACHES

    Oct 1, 2018, 00:00

  • PMS116 - HUMANISTIC AND ECONOMIC BURDEN OF X-LINKED HYPOPHOSPHATEMIA (XLH)- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN175 - BRENTUXIMAB VEDOTIN COMPARED WITH STANDARD THERAPY FOR PATIENTS WITH ADVANCED-STAGE HODGKIN’S LYMPHOMA- A COST-EFFECTIVENESS ANALYSIS

    Oct 1, 2018, 00:00

  • PCN372 - EVIDENCE MAP OF PATIENT REPORTED OUTCOME STUDIES IN NON-HODGKIN LYMPHOMA SINCE 1960

    Oct 1, 2018, 00:00

  • PMS37 - INDIRECT COSTS OF VERTEBRAL ALGIC SYNDROME

    Oct 1, 2018, 00:00

  • PSY123 - IDENTIFICATION OF THE TREATMENT ATTRIBUTES TO BE CONSIDERED IN SHARED DECISION MAKING FOR ANKYLOSING SPONDYLITIS PATIENTS- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN57 - THE ASSOCIATION BETWEEN METFORMIN EXPOSURE AND SURVIVAL AMONG DIABETIC PATIENTS WITH NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PND149 - FACTORS ASSOCIATED WITH THE CAREGIVERS’ INTENTION TO INSTITUTIONALIZE PERSONS WITH DEMENTIA

    Oct 1, 2018, 00:00

  • AD3 - EVALUATION OF THE “SOPHIA” ASTHMA PATIENT MANAGEMENT PROGRAM AT TWO YEARS

    Oct 1, 2018, 00:00

  • PSY119 - TREATMENT PATTERN ANALYSIS AND HEALTHCARE RESOURCE CONSUMPTION ON PATIENTS AFFECTED BY PSORIASIS IN APULIA REGION (ITALY).

    Oct 1, 2018, 00:00

  • PMD109 - A CANADIAN COST-UTILITY ANALYSIS OF TWO TRABECULAR MICRO-BYPASS STENTS IMPLANTED AT TIME OF CATARACT SURGERY IN PATIENTS WITH MILD-TO-MODERATE OPEN-ANGLE GLAUCOMA

    Oct 1, 2018, 00:00

  • PRM90 - DIGITAL DASHBOARD FOR MAPPING PATIENT DISTRIBUTIONS

    Oct 1, 2018, 00:00

  • PRS2 - HEALTH OUTCOMES OF MATERNAL SMOKING DURING PREGNANCY AND POSTPARTUM PERIOD FOR THE MOTHER AND INFANT- AN UMBRELLA REVIEW

    Oct 1, 2018, 00:00

  • PCN199 - HOW DO QUALITY-ADJUSTED LIFE YEARS IMPACT REIMBURSEMENT DECISION-MAKING IN THE UK?

    Oct 1, 2018, 00:00

  • PMD67 - COST-CONSEQUENCE ANALYSIS OF A HEMOSTATIC FLOWABLE MATRIX ALONE OR IN COMBINATION FOR SPINE SURGERY PATIENTS

    Oct 1, 2018, 00:00

  • PMU67 - COST-EFFECTIVENESS ANALYSIS OF IXEKIZUMAB VERSUS SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND CONCOMITANT MODERATE-TO-SEVERE PSORIASIS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PCN276 - MANAGED ACCESS AGREEMENTS UNDER THE CANCER DRUGS FUND (CDF)- KEY METRICS AND DRIVERS

    Oct 1, 2018, 00:00

  • PHP34 - TIME ANALYSIS OF THE DRUG APPROVAL PROCESS IN EUROPE

    Oct 1, 2018, 00:00

  • PHP229 - EU5 MARKET ACCESS FOR MEDICINES WITH CONDITIONAL MARKETING AUTHORISATIONS

    Oct 1, 2018, 00:00

  • PMD73 - ECONOMIC IMPACT OF THE TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA ON HIP FRACTURE- A COST-EFFECTIVENESS ANALYSIS

    Oct 1, 2018, 00:00

  • PHP7 - DIGITALIZATION AND CUSTOMER-RESPONSIVE SECONDARY CARE SERVICES POTENTIALLY FREE HEALTH CARE CAPACITY- PREDICTED MONETARY BENEFITS OF VIRTUAL HOSPITAL 2.0

    Oct 1, 2018, 00:00

  • PND8 - PEGINTERFERON BETA-1A IS ASSOCIATED WITH REDUCED RELAPSE RATES AND HOSPITALISATIONS DUE TO RELAPSE COMPARED WITH OTHER FIRST-LINE INJECTABLE THERAPIES FOR MULTIPLE SCLEROSIS- FINDINGS FROM A REAL-WORLD CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PCN27 - THE REAL-WORLD COST AND EFFECTIVENESS OF EVEROLIMUS IN METASTATIC BREAST CANCER IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PSY79 - THE COST OF MAJOR BLEEDING EVENTS ASSOCIATED WITH ANTICOAGULATION TREATMENT – AN ESTIMATION OF THE CONTRIBUTION OF THE REVERSAL AGENTS TO THE OVERALL COST OF MAJOR BLEEDING IN A UK SETTING

    Oct 1, 2018, 00:00

  • PMD129 - TRENDS IN OUTCOMES ASSOCIATED WITH ACUTE ISCHEMIC STROKE IN A US COMMERCIAL INSURANCE POPULATION

    Oct 1, 2018, 00:00

  • Economic Analysis of Vaccination Programs

    Oct 1, 2018, 00:00

  • PND102 - CARE PATHWAY DIVERSITY OF PATIENTS WITH MULTIPLE SCLEROSIS BETWEEN FRENCH REGIONS

    Oct 1, 2018, 00:00

  • PMD56 - COST OF STENT-RETRIEVER MECHANICAL THROMBECTOMY IN PATIENTS WITH ISCHEMIC STROKE IN THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PMU80 - ENHANCING MEDICATION ADHERENCE THROUGH AN ADHERENCE SUPPORT PROGRAM

    Oct 1, 2018, 00:00

  • PMD105 - EVALUATING THE COST-EFFECTIVENESS OF SCREENING FOR THE GENETIC RISK OF THROMBOSIS DURING THE RECOMMENDATION OF COMBINED HORMONAL CONTRACEPTION FOR FIRST-TIME USERS IN SWITZERLAND

    Oct 1, 2018, 00:00

  • PCN113 - EVALUATING THE ECONOMIC IMPACT OF NOVEL AGENTS FOR TREATING MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PDB39 - EMPAGLIFLOZIN FOR PATIENTS IN THE NETHERLANDS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE- A BUDGET IMPACT MODEL

    Oct 1, 2018, 00:00

  • PCV7 - COMPARATIVE EFFECTIVENESS OF ORAL PROSTACYCLIN PATHWAY DRUGS ON HOSPITALIZATION AMONG PATIENTS WITH PULMONARY HYPERTENSION- A RETROSPECTIVE ADMINISTRATIVE CLAIMS STUDY IN A MANAGED CARE POPULATION IN THE US

    Oct 1, 2018, 00:00

  • PCV147 - A TARGETED LITERATURE REVIEW OF HEALTH STATE UTILITIES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)

    Oct 1, 2018, 00:00

  • PMH78 - CARE BURDEN AND QUALITY OF LIFE OF PRIMARY CAREGIVERS OF CHILDREN WITH INTELLECTUAL DISABILITIES IN MONGOLIA- THE MEDIATING EFFECT OF FAMILY STRENGTH

    Oct 1, 2018, 00:00

  • PSS53 - ORIGINATOR AND GENERIC MARKET ACCESS PROTECTION STRATEGIES IN GERMANY USING DERMATOLOGY AS AN EXAMPLE

    Oct 1, 2018, 00:00

  • PRS1 - REAL-WORLD EVALUATION OF THE EFFECTIVENESS AND SAFETY OF PIRFENIDONE- FINDINGS FROM AN OBSERVATIONAL CHART REVIEW OF A LARGE COHORT OF IDIOPATHIC PULMONARY FIBROSIS (IPF) PATIENTS IN ITALY

    Oct 1, 2018, 00:00

  • PRM268 - EVALUATION OF REAL-WORLD DATA COLLECTION AND EVIDENCE GENERATION FROM EARLY ACCESS PROGRAM

    Oct 1, 2018, 00:00

  • PIH28 - ISAACUS DATA LAKE PRE-PRODUCTION PROJECT- CHILD PLACEMENT DECISION AND ITS COST DRIVERS

    Oct 1, 2018, 00:00

  • PND89 - BLOOD LOSS AND TRANSFUSION MANAGEMENT IN COMPLEX MULTI-LEVEL SPINE SURGERY IN EUROPE

    Oct 1, 2018, 00:00

  • MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA- INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PCV105 - POTENTIAL REDUCTION IN MORTALITY AND HOSPITALISATIONS WITH OPTIMAL USAGE OF SACUBITRIL/VALSARTAN THERAPY FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN IRELAND

    Oct 1, 2018, 00:00

  • PCN300 - MODERN TRENDS OF ORCHIECTOMY FOR PROSTATE CANCER

    Oct 1, 2018, 00:00

  • PMS93 - ASSESSMENT OF PATIENTS’ ADHERENCE ON MTX USE- A PATIENT ASSOCIATION SURVEY.

    Oct 1, 2018, 00:00

  • PSY117 - ASSESSMENT OF SOCIAL AND ECONOMIC BURDEN OF CHRONIC MYELOID LEUKEMIA IN BULGARIA

    Oct 1, 2018, 00:00

  • PIH22 - ECONOMIC IMPACT OF DONOR HUMAN MILK VERSUS FORMULA FOR VERY LOW BIRTH WEIGHT INFANTS IN THE NEONATAL INTENSIVE CARE UNIT

    Oct 1, 2018, 00:00

  • PSY136 - A COMPARISON OF PR REQUIREMENTS FOR ORPHAN DRUGS IN 25 MARKETS

    Oct 1, 2018, 00:00

  • PCN54 - IN-HOSPITAL RESOURCE USE FOR CANCER IN GERMANY FROM 2010 TO 2015

    Oct 1, 2018, 00:00

  • PIN49 - THE COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN VERSUS CASPOFUNGIN FOR CANDIDEMIA AND INVASIVE CANDIDIASIS TREATMENT- AN EXPERIENCE FROM IRAN

    Oct 1, 2018, 00:00

  • PRM173 - DISCRIMINATIVE VALIDITY OF THE EQ-5D-5L AND SF-12 IN OLDER ADULTS WITH ARTHRITIS

    Oct 1, 2018, 00:00

  • PMS16 - EFFECT OF BISPHOSPHONATES ON PERIPROSTHETIC BONE MINERAL DENSITY LOSS AFTER HIP ARTHROPLASTY- AN INDIRECT TREATMENT COMPARISON OF RANDOMIZED CONTROLLED TRIALS

    Oct 1, 2018, 00:00

  • PCN68 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN ENGLAND

    Oct 1, 2018, 00:00

  • PRS81 - PRESCRIBING PATTERN AND USE OF STEROIDS AMONG ASTHMATIC PATIENTS IN A TERTIARY CARE HOSPITAL

    Oct 1, 2018, 00:00

  • PRM260 - GENERATION OF RECONSTRUCTED INDIVIDUAL PATIENT DATA FROM DIGITIZED CURVES IN COST-EFFECTIVENESS MODEL- A DISCRETE OPTIMIZATION APPROACH

    Oct 1, 2018, 00:00

  • PND50 - SOCIAL RETURN ON INVESTMENT OF AN IDEAL APPROACH TO MULTIPLE SCLEROSIS WITHIN THE SPANISH NATIONAL HEALTH SYSTEM

    Oct 1, 2018, 00:00

  • PRM248 - REFERENCED-BASED IMPUTATION FOR THE COST-EFFECTIVENESS ANALYSIS OF LONGITUDINAL RANDOMISED TRIAL

    Oct 1, 2018, 00:00

  • PND137 - PATTERNS OF USE OF PROLONGED-RELEASE FAMPRIDINE AND PHYSIOTHERAPY AMONG PATIENTS WITH MS IN TWO LARGE MULTI-COUNTRY STUDY COHORTS

    Oct 1, 2018, 00:00

  • PRM228 - EXTRAPOLATION OF SURVIVAL CURVES USING EXTERNAL INFORMATION- IMPLEMENTATION OF GUYOT’S METHOD IN PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PCN364 - EVALUATING PSYCHOMETRIC PROPERTIES OF UK EQ-5D-5L SCORING ALGORITHMS IN METASTATIC MERKEL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PSY14 - CLINICAL RESPONSE TO SYSTEMIC TREATMENTS FOR STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMS44 - COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS TOCILIZUMAB PLUS METHOTREXATE IN RHEUMATOID ARTHRITIS TREATMENT

    Oct 1, 2018, 00:00

  • PCN389 - QUALITY OF LIFE USING EQ-5D-3L MEASURE BEFORE ICU ADMISSION TO PREDICT THE MORTALITY OF CRITICALLY ILL CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PMS96 - A DEMAND SURVEY ON PATIENT EDUCATION FOR PATIENTS WITH RHEUMATOID ARTHRITIS

    Oct 1, 2018, 00:00

  • PHP146 - ANALYSES OF THE PERFORMANCE INDICATORS OF REHABILITATION AND CHRONIC INPATIENT CARE IN HUNGARY BETWEEN 1990 AND 2016

    Oct 1, 2018, 00:00

  • PCV119 - BASELINE HEALTH RELATED QUALITY OF LIFE IN PATIENTS ADMITTED BY HEART FAILURE. DOES GENDER MATTER?

    Oct 1, 2018, 00:00

  • PHP236 - QUALITY OF EVIDENCE ON THE COST-EFFECTIVENESS OF DRUGS PROPOSED FOR THE INCLUSION IN THE RUSSIAN VITAL AND ESSENTIAL DRUGS LIST IN 2014-2017

    Oct 1, 2018, 00:00

  • PIH50 - RESILIENCE AND ITS INFLUENCING FACTORS’ EFFECT ON TIMELY APPEARENCE OF 2ND AND 3RD PHASE OF LACTOGENESIS

    Oct 1, 2018, 00:00

  • PCV151 - WHAT ARE THE MOST VALUED PATIENT OUTCOMES REGARDING MEDICAL CARE FOR FRENCH PATIENTS WITH HEART FAILURE? RESULTS FROM AN ONLINE PATIENT COMMUNITY (CARENITY.COM)

    Oct 1, 2018, 00:00

  • PMS112 - PATIENT AND RHEUMATOLOGIST PREFERENCES FOR THE ATTRIBUTES OF RHEUMATOID ARTHRITIS TREATMENTS IN SPAIN. A DISCRETE CHOICE EXPERIMENT

    Oct 1, 2018, 00:00

  • PIN18 - ESTIMATING THE BUDGET AND CLINICAL IMPACT OF INTRODUCING ISAVUCONAZOLE FOR THE TREATMENT OF PATIENTS WITH POSSIBLE INVASIVE ASPERGILLOSIS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PCV111 - CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS AMONG PATIENTS WITH VENOUS THROMBOEMBOLISM PRESCRIBED ANTICOAGULANTS IN GERMANY

    Oct 1, 2018, 00:00

  • PMS95 - DO DISAGREEMENTS BETWEEN PATIENT AND POPULATION VALUATIONS DIFFER BY SOCIO-DEMOGRAPHIC GROUP AND/OR HEALTH STATUS? AN EXPLORATORY STUDY AMONG CHRONIC LOW BACK PAIN PATIENTS

    Oct 1, 2018, 00:00

  • PMS109 - PREVENTION OF SHOULDER JOINT INJURIES IN WATER POLO WITH STRETCHING AND STABILIZATION TECHNIQUES

    Oct 1, 2018, 00:00

  • PUK17 - A COST-EFFECTIVENESS ANALYSIS OF RAASI – ENABLING PATIROMER FOR THE TREATMENT OF HYPERKALEMIA IN SWEDEN

    Oct 1, 2018, 00:00

  • PCN97 - ASSESSING THE IMPACT OF ACTIVE IDENTIFICATION OF PATIENTS APPROPRIATE FOR PALLIATIVE CARE ON RESOURCE UTILIZATION AND COSTS IN THE FINAL MONTH OF LIFE

    Oct 1, 2018, 00:00

  • PRM147 - OPEN-SOURCE MODELS IN HEALTH ECONOMICS- EXPERIENCE BASED ON A DISCRETE EVENT SIMULATION MODEL IN MAJOR DEPRESSIVE DISORDER

    Oct 1, 2018, 00:00

  • PND86 - ECONOMIC BENEFITS ON ADULT UPPER LIMB SPASTICITY TREATMENT WITH ABOBOTULINUMTOXIN-A COMPARED TO ONABOTULINUMTOXIN-A OR INCOBOTULINUMTOXIN-A- ANALYSES IN A REAL-LIFE SETTING IN FRANCE

    Oct 1, 2018, 00:00

  • PMD17 - COMPARISON OF ECONOMIC AND CLINICAL OUTCOMES BETWEEN BARBED AND CONVENTIONAL SUTURES AMONG PATIENTS UNDERGOING SPINE SURGERY

    Oct 1, 2018, 00:00

  • PDB119 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH MEALTIME INSULIN CONCENTRATIONS AMONG PATIENTS WITH DIABETES IN ITALY

    Oct 1, 2018, 00:00

  • PRS61 - ASSESSMENT OF ASTHMA-DIAGNOSED POPULATION ELIGIBLE FOR NEW MONOCLONAL ANTIBODY THERAPY IN VENETO REGION

    Oct 1, 2018, 00:00

  • PRM16 - AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) LEVEL PREDICTION IN POPULATION-BASED ADMINISTRATIVE DATABASES IN THE ABSENCE OF RECORDED LABORATORY VALUES

    Oct 1, 2018, 00:00

  • PMD12 - AMBULATORY BLOOD PRESSURE MONITORING IN THE DIAGNOSIS AND MANAGEMENT OF ARTERIAL HYPERTENSION IN CURRENT MEDICAL PRACTICE IN ALGERIA- MAPA DZ STUDY - INTERIM ANALYSIS

    Oct 1, 2018, 00:00

  • PCN293 - WHAT IS THE VALUE OF REAL WORLD EVIDENCE IN ONCOLOGY IN HTA APPRAISALS IN ENGLAND, FRANCE, CANADA AND AUSTRALIA?

    Oct 1, 2018, 00:00

  • PIH13 - ABIRATERONE- A SINGLE-CENTRE EXPERIENCE

    Oct 1, 2018, 00:00

  • PSS62 - TREATMENT PREFERENCE DRIVERS OF PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

    Oct 1, 2018, 00:00

  • PCV138 - TREATMENT PATTERNS OF PATIENTS WITH VENOUS THROMBOEMBOLISM TREATED WITH ORAL ANTICOAGULANTS IN ENGLAND

    Oct 1, 2018, 00:00

  • PRS16 - MODELED SURVIVAL GAINS OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGED ≥12 YEARS HETEROZYGOUS FOR F508DEL-CFTR AND A RESIDUAL FUNCTION MUTATION (F508DEL/RF) TREATED WITH THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR (CFTRM) TEZACA ...

    Oct 1, 2018, 00:00

  • PCN192 - ROBOTIC VERSUS LAPAROSCOPIC DISTAL PANCREATECTOMY- A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS ANALYSIS

    Oct 1, 2018, 00:00

  • PHP115 - COMPARATIVE ANALYSIS OF THE MARKET PENETRATION OF PERSONALISED MEDICINE DRUGS UNDER THE CONDITIONS OF AMNOG

    Oct 1, 2018, 00:00

  • PHP54 - DIRECTIVE 2004/18/EC- IMPLICATIONS FOR PUBLIC MEDICINE PROCUREMENT IN EUROPE

    Oct 1, 2018, 00:00

  • PMH69 - QUALITY OF LIFE ACCORDING TO RESPONDER RATE IN OPIOID DEPENDENT ADULTS RECEIVING TREATMENT WITH BUPRENORPHINE DEPOT INJECTIONS (CAM2038) VERSUS SUBLINGUAL BUPRENORPHINE/NALOXONE

    Oct 1, 2018, 00:00

  • PCN55 - TYPE-SPECIFIC DATA ON HUMAN PAPILLOMAVIRUS INFECTION IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA IN THE ASIA-PACIFIC REGION

    Oct 1, 2018, 00:00

  • PMS75 - SEEKING THE STATE OF THE ART IN STANDARDIZED MEASUREMENT OF HEALTH CARE RESOURCE USE AND COSTS IN JUVENILE IDIOPATHIC ARTHRITIS- A SCOPING REVIEW

    Oct 1, 2018, 00:00

  • PCN38 - NIVOLUMAB IS PREDICTED TO HAVE IMPROVED CLINICAL OUTCOMES OVER BEST SUPPORTIVE CARE IN A WESTERN POPULATION OF PRE-TREATED GASTRIC CANCER PATIENTS; AN INDIRECT TREATMENT COMPARISON ANALYSIS

    Oct 1, 2018, 00:00

  • PIN62 - COST-EFFECTIVENESS OF PNEUMOCOCCAL CONJUGATE VACCINES IN A COHORT OF NEWBORNS IN COLOMBIA

    Oct 1, 2018, 00:00

  • PRM109 - EXPLORING THE USE AND ACCEPTANCE OF ALTERNATIVE SURVIVAL MODELLING APPROACHES FOR IMMUNO-ONCOLOGY THERAPIES IN UK TECHNOLOGY ASSESSMENTS

    Oct 1, 2018, 00:00

  • PHP231 - ADOPTION OF INNOVATIONS IN THE GERMAN DRG-SYSTEM – A QUANTITATIVE ANALYSIS

    Oct 1, 2018, 00:00

  • PCV40 - BUDGET IMPACT ANALYSIS OF RIVAROXABAN IN THE SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES IN GREECE

    Oct 1, 2018, 00:00

  • CV3 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN GERMANY- APPLYING THE EFFICIENCY THRESHOLD

    Oct 1, 2018, 00:00

  • PGI30 - POLISH THERAPEUTIC ALGORITHMS IN PATIENTS WITH COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE

    Oct 1, 2018, 00:00

  • PND140 - IMPACT OF MIGRAINE ON WORK PRODUCTIVITY IN PORTUGUESE PATIENTS

    Oct 1, 2018, 00:00

  • PCN246 - EVOLUTION OF ONCOLYTICS CONSUMPTION IN PORTUGAL OVER TEN YEARS

    Oct 1, 2018, 00:00

  • PSY212 - TREATMENT CHARACTERISTICS, QUALITY OF LIFE AND SLEEP PERFORMANCE OF LOCALISED NEUROPATHIC PAIN PATIENTS IN THE PRIMARY CARE SETTING

    Oct 1, 2018, 00:00

  • PCN351 - HEALTH-STATE UTILITY VALUES IN DIFFUSE LARGE B-CELL LYMPHOMA

    Oct 1, 2018, 00:00

  • PHP219 - MEDICINRÅDET AND THE NEW HOSPITAL DRUG APPRAISAL PROCESS IN DENMARK – THE STORY SO FAR

    Oct 1, 2018, 00:00

  • PCP64 - DEVELOPMENT AND VALIDATION OF COGNITIVE PERFORMANCE-BASED OUTCOME (PERFO) ASSESSMENTS

    Oct 1, 2018, 00:00

  • PCN59 - ASSOCIATION BETWEEN HAZARD RATIOS OF SURROGATE TIME-TO-EVENT ENDPOINTS AND OVERALL SURVIVAL IN ADVANCED/METASTATIC CANCERS

    Oct 1, 2018, 00:00

  • PRM187 - A SYSTEMATIC REVIEW OF UTILITY ESTIMATES IN MELANOMA IN THE ADJUVANT SETTING

    Oct 1, 2018, 00:00

  • PMD41 - THE BUDGET IMPACT AND COST-CONSEQUENCE OF TREATING DIABETIC FOOT ULCERS WITH URGOSTART

    Oct 1, 2018, 00:00

  • PCN216 - CONTEMPORARY REAL-WORLD EVIDENCES ON ALK+ NSCLC PATIENTS IN ITALY

    Oct 1, 2018, 00:00

  • PRM245 - EXTRAPOLATION OF SURVIVAL IN THE CONTEXT OF ECONOMIC MODELLING USING BAYESIAN MODEL AVERAGING- AN APPLICATION IN RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PDB81 - DAPAGLIFLOZIN IS COST-EFFECTIVE COMPARED TO DPP-4 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PND63 - COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN

    Oct 1, 2018, 00:00

  • PRM112 - INCORPORATION OF ANTI-CANCER DRUGS ADVERSE EVENTS IN HEALTH ECONOMIC OPINIONS OF THE FRENCH NATIONAL AUTHORITY FOR HEALTH (HAS)

    Oct 1, 2018, 00:00

  • PRS101 - IMPACT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ON QUALITY OF LIFE- FINDINGS FROM A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP126 - SCARS OF CHILD POVERTY IN ADULTS- A HEALTH PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN232 - VARIATION IN ACCESS TO PD-1 IMMUNOTHERAPIES IN EUROPE

    Oct 1, 2018, 00:00

  • PND44 - A NEW APPROACH FOR ESTIMATING AND VISUALISING SOCIETAL COSTS- AN EXAMPLE IN MULTIPLE SCLEROSIS IN ENGLAND

    Oct 1, 2018, 00:00

  • PSY125 - PHYSICIANS' AND PHARMACISTS’ PRIORITIES IN TREATMENT DECISION-MAKING FOR CHRONIC LYMPHOCYTIC LEUKEMIA

    Oct 1, 2018, 00:00

  • PIN105 - THE PUBLIC HEALTH IMPACT OF TICK-BORNE ENCEPHALITIS VACCINATION ON THE SLOVENIAN ADULT POPULATION

    Oct 1, 2018, 00:00

  • PHP367 - PROFESSIONALS’ PERSPECTIVE OF FACTORS INFLUENCING THE DEVELOPMENT OF A SUCCESSFUL PHARMACEUTICAL PRODUCT. THEMATIC ANALYSIS

    Oct 1, 2018, 00:00

  • PSS12 - PREVALENCE OF NEUROTROPHIC KERATOPATHY IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PSY86 - HIGHER LEVELS OF SKIN CLEARANCE ARE ASSOCIATED WITH DECREASED INDIRECT COSTS RELATED TO PRODUCTIVITY LOSS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

    Oct 1, 2018, 00:00

  • PCV11 - MODELING CARDIOVASCULAR EVENT REDUCTION THROUGH LOW-DENSITY LIPOPROTEIN REDUCTION IN COST-EFFECTIVENESS ANALYSES- A META-REGRESSION APPROACH

    Oct 1, 2018, 00:00

  • PSY128 - HOW LONG CAN THE ORPHAN DRUG EXCLUSIVITY PERIOD BE EXTENDED, AND AT WHAT COST?

    Oct 1, 2018, 00:00

  • PCP59 - IDENTIFICATION, SELECTION AND MEASUREMENT OF OUTCOMES TO FACILITATE THE USE OF BIG DATA- A TOOLKIT

    Oct 1, 2018, 00:00

  • PCN76 - BUDGET IMPACT ANALYSIS OF AFATINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC NON–SMALL-CELL LUNG CANCER IN CHINA

    Oct 1, 2018, 00:00

  • PND20 - INCIDENCE AND TREATMENT OF PATIENTS WITH STATUS EPILEPTICUS- AN ANALYSIS OF GERMAN CLAIMS DATA

    Oct 1, 2018, 00:00

  • PCN90 - COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF NILOTINIB FOR THE SECOND LINE TRATMENT OF CHRONIC MIELOID LEUKEMIA IN THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PIN51 - COST-EFFECTIVENESS OF LEDIPASVIR/SOFOBUVIR IN HEPATITIS C TREATMENT- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PRM105 - REAL WORLD EVIDENCE- DOES THE POPULARITY OF THE TERM REFLECT IN PUBLICATION NUMBERS?

    Oct 1, 2018, 00:00

  • PDB53 - EVALUATING THE RELATIONSHIP BETWEEN GLYCEMIC CONTROL, INCIDENCE OF SEVERE HYPOGLYCEMIA, AND LONG-TERM HEALTH ECONOMIC OUTCOMES IN PATIENTS WITH TYPE 1 DIABETES IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PMU19 - RISK OF COMPLICATIONS FOLLOWING OPEN OR MINIMALLY INVASIVE PULMONARY WEDGE RESECTIONS- A PROPENSITY SCORE ANALYSIS

    Oct 1, 2018, 00:00

  • PSY47 - AN ECONOMIC EVALUATION OF IRON ISOMALTOSIDE 1000 VERSUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANEMIA IN DENMARK

    Oct 1, 2018, 00:00

  • PHP228 - THE IMPACT OF LABEL EXTENSIONS ON THE REIMBURSED PRICE OF PHARMACEUTICAL PRODUCTS ASSESSED ACCORDING TO §35A SGB V IN GERMANY - ONCOLOGICAL AND METABOLIC DISEASES

    Oct 1, 2018, 00:00

  • PRM199 - STAKEHOLDER PERSPECTIVES ON CONDUCT AND USE OF PATIENT PREFERENCE STUDIES ALONG THE MEDICAL PRODUCT LIFECYCLE- RESULTS FROM FOCUS GROUPS

    Oct 1, 2018, 00:00

  • PRS50 - COST-EFFECTIVENESS ANALYSIS OF SURFACTANT THERAPY FOR THE TREATMENT OF RESPIRATORY DISTRESS SYNDROME NEWBORN IN THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PMH41 - COST-UTILITY ANALYSES OF INFORMAL CAREGIVER INTERVENTIONS- A CRITICAL REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PMS64 - MULTIPLE SCLEROSIS AND WORKABILITY IN ITALY- THE ECONOMIC EFFECT OF NATALIZUMAB ON THE ABILITY TO WORK

    Oct 1, 2018, 00:00

  • PMS72 - ASSOCIATION BETWEEN HIGH CONCENTRATION NON-AVIAN HIGH MOLECULAR WEIGHT HYALURONAN AND TIME-TO-TOTAL KNEE REPLACEMENT SURGERY AMONG COMMERCIALLY-INSURED PATIENTS WITH KNEE OSTEOARTHRITIS IN THE UNITED STATES- A RETROSPECTIVE STUDY WI ...

    Oct 1, 2018, 00:00

  • PIN64 - DOLUTEGRAVIR PLUS LAMIVUDINE FOR THE TREATMENT OF NAÏVE ADULTS LIVING WITH HIV-1- A UK COST-MINIMIZATION ANALYSIS

    Oct 1, 2018, 00:00

  • PCN75 - BUDGET IMPACT MODEL OF SUBCUTANEOUS TRASTUZUMAB COMPARED WITH INTRAVENOUS TRASTUZUMAB ON THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PHP239 - THE INTRODUCTION AND IMPLICATIONS OF THE COST-CONTAINMENT MEASURE ‘THE SLUICE’ FOR EXPENSIVE INNOVATIVE DRUGS IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PCN283 - IDENTIFYING THE KEY CHALLENGES AFFECTING THE REIMBURSEMENT OF CAR-T THERAPIES IN THE EU5 USING A WEB-BASED PORTAL TO ENGAGE PAYERS

    Oct 1, 2018, 00:00

  • PCN143 - HEALTH ECONOMIC EVALUATION OF BIOLOGIC AGENTS FOR METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL

    Oct 1, 2018, 00:00

  • PIH51 - THE EFFECT OF EXERCISING ON SEXUAL FUNCTIONS IN POST-MENOPAUSAL WOMEN

    Oct 1, 2018, 00:00

  • PCN173 - COST-EFFECTIVENESS OF NEW TRIPLET COMBINATIONS WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PSY37 - SYSTEMATIC LITERATURE REVIEW ON THE WORLDWIDE EPIDEMIOLOGY OF PROPIONIC ACIDEMIA

    Oct 1, 2018, 00:00

  • PCP13 - IMPACT OF OUTCOME BASED ANNUITIES ON SMALL BIOTECH COMPANIES

    Oct 1, 2018, 00:00

  • PCN381 - REFERENCE VALUES FOR EORTC QLQ-C30 IN HODGKIN’S LYMPHOMA

    Oct 1, 2018, 00:00

  • PSY45 - BUDGET IMPACT ANALYSIS OF THE PATIENT BLOOD MANAGEMENT FROM A FRENCH NATIONAL PAYER AND HOSPITAL PERSPECTIVES IN FRANCE

    Oct 1, 2018, 00:00

  • PHP143 - ECONOMIC EVALUATIONS AND BUDGET IMPACT ANALYSES OF INNOVATIVE MEDICINES ACCORDING TO THE CATALAN HEALTH SERVICE STANDARDS- A QUALITATIVE ASSESSMENT

    Oct 1, 2018, 00:00

  • PCN214 - IBRITUMOMAB TIUXETAN RADIOLABELLED WITH YTTRIUM CHLORIDE- 4 YEARS OF USE IN THE 37 PUBLIC HOSPITALS OF PARIS AND IN FRANCE

    Oct 1, 2018, 00:00

  • PCN32 - THE EFFECTIVENESS AND SAFETY OF SWITCHING FROM ORGINAL FILGRASTIM TO BIOSIMILAR FILGRASTIM IN PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA- A RETROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PMU54 - HOW MUCH DOES IT COST TO TRAIN A PHYSICIAN IN COLOMBIA?

    Oct 1, 2018, 00:00

  • AD1 - ASSOCIATION OF ADHERENCE AND TREATMENT INTENSITY WITH CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ATHEROSCLEROSIS OR OTHER CARDIOVASCULAR RISK FACTORS TREATED WITH STATINS AND/OR EZETIMIBE

    Oct 1, 2018, 00:00

  • PHP337 - OFF-LABEL PRESCRIPTION OF DRUGS COMPARED TO PRESCRIPTION AFTER LABEL EXTENSION IN CHILDREN FOR GERMANY

    Oct 1, 2018, 00:00

  • PCN167 - IMPROVEMENT OF AN OPEN-SOURCE COST-EFFECTIVENESS MODEL BASED ON PUBLIC FEEDBACK

    Oct 1, 2018, 00:00

  • PRM266 - 50 MILLION TESTS AND CONFOUNDING- THE PROMISES AND CHALLENGES OF BIG DATA

    Oct 1, 2018, 00:00

  • PMH45 - MODELLING THE BUDGETARY IMPACT OF TREATING OPIOID ADDICTION IN THE ENGLISH MUNICIPAL SETTING

    Oct 1, 2018, 00:00

  • PHP332 - INTRODUCTION OF MOBILE HEALTH TECHNOLOGY AT THE PRIMARY HEALTHCARE LEVEL IN MONGOLIA

    Oct 1, 2018, 00:00

  • PHP285 - EXPERTS IN HEALTH TECHNOLOGY ASSESSMENT ARE CONCERNED ABOUT THE TRANSLATION FROM EVIDENCE TO DECISION-MAKING

    Oct 1, 2018, 00:00

  • PCN347 - EXPLORING THE IMPACT OF RADIOGRAPHIC PROGRESSIVE DISEASE AND FIRST SUBSEQUENT THERAPY ON HEALTH STATE UTILITY VALUES IN GERMLINE-BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSROC) PATIENTS ON OLAPARIB TABLETS ...

    Oct 1, 2018, 00:00

  • PMH25 - EARLY ADMINISTRATION OF ARIPIPRAZOLE LONG-ACTING INJECTABLE IN ACUTE INPATIENTS WITH SCHIZOPHRENIA REDUCES THE COST OF HOSPITALIZATION

    Oct 1, 2018, 00:00

  • PSY211 - THE CLINICAL, HUMANISTIC, AND ECONOMIC BURDEN OF ADENOSINE DEAMINASE (ADA) SEVERE COMBINED IMMUNODEFICIENCY (SCID)- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PRM124 - MODELLING LIKELY CARDIOVASCULAR DISEASE MORTALITY WITH PCSK9 INHIBITORS USING A SYNTHETIC POPULATION

    Oct 1, 2018, 00:00

  • PSY177 - HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH BETA-THALASSEMIA

    Oct 1, 2018, 00:00

  • PCN289 - HOW ACCELARATED IS PATIENTS’ ACCESS TO NEW ONCOLOGY PRODUCTS IN THE NEW ERA OF CANCER DRUG’S FUND IN ENGLAND?

    Oct 1, 2018, 00:00

  • PCN286 - INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIA

    Oct 1, 2018, 00:00

  • AC3 - DISCORDANT DESIGNATIONS OF BREAKTHROUGH DRUG INNOVATION- FRANCE VERSUS THE UNITED STATES

    Oct 1, 2018, 00:00

  • PMD119 - SYSTEMATIC REVIEW ON CLINICAL OUTCOMES OF ULTRASONIC TECHNOLOGY FOR PATIENTS UNDERGOING COLORECTAL ONCOLOGY PROCEDURES

    Oct 1, 2018, 00:00

  • PMD94 - ECONOMIC EVALUATION OF ACCU-CHEK ® INSTANT S GLUCOMETER FOR THE SELF-MONITORING GLUCOSE (SMG) IN PATIENTS WITH DIABETES MELLITUS (DM), FROM THE VIEW OF THE PUBLIC HEALTHCARE SYSTEM IN MEXICO.

    Oct 1, 2018, 00:00

  • PCN277 - PREDICTORS OF HOSPITALIZATIONS AND EMERGENCY DEPARTMENT (ED) VISITS IN SECOND-LINE (2L) ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)

    Oct 1, 2018, 00:00

  • PND65 - COST-EFFECTIVENESS ANALYSIS OF DRUGS USED FOR THE TREATMENT OF HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PND57 - THE COST-EFFECTIVENESS OF ALEMTUZUMAB IN THE MANAGEMENT OF RELAPSE-REMITTING MULTIPLE SCLEROSIS IN ITALY

    Oct 1, 2018, 00:00

  • PSY158 - A PRAGMATIC LITERATURE REVIEW TO IDENTIFY ECONOMIC OUTCOMES FOR REPURPOSED DRUGS IN RARE DISEASES

    Oct 1, 2018, 00:00

  • PMU97 - OLDER ADULTS SATISFACTION WITH PHARMACEUTICAL CARE IN AN OUTPATIENT PHARMACY OF A NIGERIAN TEACHING HOSPITAL

    Oct 1, 2018, 00:00

  • PMU92 - CAN THE EQ-5D-3L PREDICT POST-HOSPITALIZATION HEALTHCARE USE AND OUTCOMES?

    Oct 1, 2018, 00:00

  • PHP211 - ESTIMATION OF PHARMACEUTICAL CARE SERVICES IN UKRAINE- ISSUES AND WAYS FOR IMPROVEMENT

    Oct 1, 2018, 00:00

  • PSS49 - EPIDEMIOLOGY AND TREATMENT PATTERNS IN ADULT PATIENTS WITH ATOPIC DERMATITIS- ANALYSIS OF LONGITUDINAL DATA FROM THE GERMAN STATUTORY HEALTH INSURANCE SYSTEM

    Oct 1, 2018, 00:00

  • PCN17 - INDIRECT TREATMENT COMPARISONS OF NIVOLUMAB VERSUS REGORAFENIB, CABOZANTINIB AND BEST SUPPORTIVE CARE AFTER TREATMENT WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMA

    Oct 1, 2018, 00:00

  • DB3 - PROOF-OF-CONCEPT STUDY OF DIGITAL SMARTPHONE APPLICATIONS TO SUPPORT SELF-MANAGEMENT OF LONG-TERM HEALTH CONDITIONS

    Oct 1, 2018, 00:00

  • PCP3 - ADAPTIVE PATHWAYS 2020- WHAT’S ON THE HORIZON IN THE NEXT 2-3 YEARS?

    Oct 1, 2018, 00:00

  • PSY160 - REAL WORLD TREATMENT PATTERNS AND RESOURCE UTILIZATION IN PULMONARY ARTERIAL HYPERTENSION IN BRAZIL- A PUBLIC HEALTHCARE DATABASE STUDY

    Oct 1, 2018, 00:00

  • PP1 - CONSIDERATIONS FOR USING A WEB-BASED SYSTEM TO COLLECT PATIENT-REPORTED OUTCOME (PRO) DATA

    Oct 1, 2018, 00:00

  • PCV83 - KEY MODEL PARAMETERS AND METHODOLOGIES USED IN COST-EFFECTIVENESS ANALYSIS EVALUATING TREATMENTS FOR SECONDARY PREVENTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) IN PATIENTS WITH A PRIOR MYOCARDIAL INFARCTION (MI) OR ACUTE COR ...

    Oct 1, 2018, 00:00

  • PRS20 - HEALTH PLAN COVERAGE OF SMOKING CESSATION TREATMENT WITH DRUG THERAPY IS COST-EFFECTIVE? A HEALTHCARE PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2018, 00:00

  • PCV126 - A COST-EFFECTIVENESS THRESHOLD BASED ON THE MARGINAL RETURNS OF CARDIOVASCULAR HOSPITAL SPENDING

    Oct 1, 2018, 00:00

  • PRM24 - A JOINT MODEL OF COGNITIVE DECLINE AND TIME TO DIAGNOSIS TO IMPROVE PREDICTIONS OF THE RISK OF DEVELOPING ALZHEIMER’S DISEASE

    Oct 1, 2018, 00:00

  • PSS8 - IDENTIFYING THE CONFOUNDERS THAT EXPLAIN THE DIFFERENCE IN READOUTS BETWEEN NON-INTERVENTIONAL STUDIES (NIS) AND RANDOMIZED CONTROLLED TRIALS (RCTS)- THE CASE OF TREATMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)

    Oct 1, 2018, 00:00

  • PHP107 - THE STRUCTURE OF CONSUMPTION OF ANTIMICROBIAL DRUG FOR SYSTEMIC USE IN MULTIDISCIPLINARY HOSPITALS IN ST.PETERSBURG IN 2014-2015

    Oct 1, 2018, 00:00

  • PCN117 - HEALTHCARE EXPENDITURES FOR THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA IN JAPAN

    Oct 1, 2018, 00:00

  • PND139 - IMPACT OF PROLONGED-RELEASE FAMPRIDINE ON FATIGUE AMONG PEOPLE WITH MULTIPLE SCLEROSIS IN A MULTI-COUNTRY STUDY

    Oct 1, 2018, 00:00

  • PRM206 - THE PERIODIC SYSTEMATIC REVIEW FOR BIBLIOPRO- A DECADE OF SPANISH PATIENT-REPORTED OUTCOMES.

    Oct 1, 2018, 00:00

  • PSS64 - A PREFERENCE STUDY INVESTIGATING PATIENT CHOICE FOR TREATING SEVERE CHRONIC SPONTANTEOUS/IDIOPATHIC URTICARIA (CSU/CIU)

    Oct 1, 2018, 00:00

  • PCN140 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VS CRIZOTINIB IN FIRST LINE ANAPLASTIC LYMPHOMA KINASE POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN PORTUGAL

    Oct 1, 2018, 00:00

  • PDB46 - CLINICAL AND ECONOMIC BURDEN OF TYPE 1 DIABETES IN REAL-LIFE SETTING IN SPAIN

    Oct 1, 2018, 00:00

  • PSS46 - DIFFERENCES IN HTA COVERAGE RECOMMENDATIONS- COMPARING OPHTHALMOLOGY DRUG REIMBURSEMENT DECISIONS IN FOUR EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PRM201 - PRESCRIPTION, ILLICIT AND HOMEOPATHIC DRUGS - ISSUES FACED IN LANGUAGE AND CULTURAL RELEVANCE WHEN REFERRING TO MEDICATION IN COAS.

    Oct 1, 2018, 00:00

  • PRS74 - ANTI-PNEUMOCOCCAL VACCINATION STRATEGY. STUDY AND PRELIMINARY RWD DECREASING GERIATRICS HOSPITAL ADMISSIONS AND CARE COSTS

    Oct 1, 2018, 00:00

  • PDB43 - THE COSTS AND RESULTS OF INCRETINS’AND SGLT-2I DIABETES THERAPY IN BULGARIA

    Oct 1, 2018, 00:00

  • PRS68 - HEALTH RESOURCE UTILIZATION (HRU) AMONG INFANTS DIAGNOSED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN THE NETHERLANDS- A RETROSPECTIVE DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PCV25 - LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF STATIN INTOLERANT PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY

    Oct 1, 2018, 00:00

  • PSY33 - FEASIBILITY OF EVALUATING THE BURDEN OF B-THALASSEMIA WITH GERMAN CLAIMS DATA

    Oct 1, 2018, 00:00

  • PIN99 - DOES A CHANGE IN VACCINATION SCHEME AFFECT PNEUMOCOCCAL CONJUGATE VACCINATION ADHERENCE? COMPARISON OF QUOTAS AND ADHERENCE IN MATURE BORN INFANTS IN GERMANY

    Oct 1, 2018, 00:00

  • PRM195 - THE INFANT GASTROESOPHAGEAL REFLEX DISEASE QUESTIONNAIRE (I-GERQ-R)- A META-ANALYSIS

    Oct 1, 2018, 00:00

  • PRM194 - INVESTIGATING THE RELATIONSHIP BETWEEN AGE AND EXPANDED DISABILITY STATUS SCALE SCORE IN UNTREATED AND CHENODEOXYCHOLIC ACID-TREATED CEREBROTENDINOUS XANTHOMATOSIS PATIENTS

    Oct 1, 2018, 00:00

  • PDB118 - SYSTEMATIC EDUCATION IN PATIENTS WITH T2DM SIGNIFICANTLY IMPROVES ADHERENCE TO THE TREATMENT. THE ADVICE STUDY

    Oct 1, 2018, 00:00

  • PMU30 - BUDGET AND HEALTH IMPACT OF IMMUNO-ONCOLOGY TREATMENTS IN ITALY

    Oct 1, 2018, 00:00

  • PCN324 - EXAMINING HPV VACCINATION PRACTICES AND DIFFERENCES AMONG PROVIDERS IN VIRGINIA

    Oct 1, 2018, 00:00
  • «
  • 51 (current)
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • »